Editorial Volume 2 Issue 5
Anesthesiologist, Iran
Correspondence: Helen Gharaei, Anesthesiologist, Pain Specialist, MD-FIPP, Milad Hospital, Iran, Tel +989198923151
Received: July 12, 2015 | Published: July 31, 2015
Citation: Gharaei H (2015) Epidural Steroid Injection Warning & Safety Recommendations. J Anesth Crit Care Open Access 2(5): 00069. DOI: 10.15406/jaccoa.2015.02.00069
A recent rapid increase in the utilization of epidural steroid injection (ESI) for the treatment of spine pain lead to many negligence claims. This procedure nearly doubled since 2000. In 2012, more than one million claims reported.1 In the 2000s, chronic pain management involved 18%, acute pain management 9% and obstetric anaesthesia formed 8% of claims, while epidural injections were the most common chronic pain injection.2 The Food and Drug Administration (FDA) issued a warning letter in 2014, that ESIs is dangerous and may lead to spinal cord infarction, paralysis, quadriplegia, paraparesis/paraplegia, stroke, bowel/bladder dysfunction, cauda equina syndrome, thrombosis/thromboembolism, sensory disturbances, blindness (transient and possible permanent), seizures, psychological/behavioral changes, sever disability and death.3,4 While the FDA does not control medicine but announce warn issues that can affect medicine. In 2009 Rathmell reported complication of ESIs to FDA. According to this report, FDA safety review begun. Issues that have been studied since that time include: label kelong not approval for epidural use, injection is not safe in arachnoiditis, survey of meningitis outbreak due to ESIs, classes and communication about the dangers of injection and ADDPAC (anesthetic and analgesic drug products Advisory Committee) meeting 2014.5
With the advancement of pain education, it seems necessary to warn about the use of epidural corticosteroid more and more. We should educate our patients about side effects of the injections at discharge time that in the case of complication refer to emergency department as soon as possible to prevent irreversible neurologic events. Following are safety recommendation that may reduce risks to patients and should facilitate defend physicians from claims:- Remember, this injection is a procedure that must follow the general rules of all procedures. Provide detailed informed consent. Take a careful history. Inform diabetic patients concerning augmented risk of infection in addition the likelihood of hyperglycemia. Raise concerning the utilization of antiplatelet medicine and anticoagulants. Be familiar with contraindications to corticosteroids. Perform physical examination and document preexistent neurologic abnormalities and search for any skin bruising or anatomic variation.6
There is an increased probability of neurologic injury once particulate steroids are used for transforaminal injections. Minimize the number of steroid injections, considering a repeat injection of steroids after minimum of two weeks. Take under consideration use of non-particulate steroids. Although, there's very little proof that soluble steroids have equivalent effectiveness, and early studies indicated that soluble steroid preparations stay within in the spinal canal just for transient periods.4,5,15,23–25 Local anesthetic could also be as effective as either particulate or non-particulate steroids.15 Particles larger than twenty microns in a solution additionally will increase the probability of vascular occlusion, mix steroids with caution, particularly with lidocaine. If the drug combination is necessary, be injected immediately.26
What is clear is that if complications occur it would be devastating. Doctors skills is important, especially because many of these doctors have not completed the pain fellowship training. Physician may be a candidate for the injections should be approved by the Medical Council for scientific and practical qualifications. Epidural and transforaminal steroid injections is in the scope of pain specialists, and should be complete by the people who are active (not essentially exclusively) in the field of pain.
None.
The authors declare that there are no conflicts of interest.
None.
©2015 Gharaei. This is an open access article distributed under the terms of the, which permits unrestricted use, distribution, and build upon your work non-commercially.